NCT01963481View on ClinicalTrials.gov

Exemestane and Cyclophosphamide for Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 1, 2017

Study Completion Date

October 1, 2017

Conditions
Metastatic Beast Cancer
Interventions
DRUG

Exemestane

DRUG

Cyclophosphamide

Trial Locations (1)

10016

NYU Cancer Center, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT01963481 - Exemestane and Cyclophosphamide for Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter